EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Open Access
- 30 May 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (11), 2941-2951
- https://doi.org/10.1158/1078-0432.ccr-12-3247
Abstract
Purpose: The mesenchymal–epithelial transition factor (c-Met) receptor, also known as hepatocyte growth factor receptor (HGFR), controls morphogenesis, a process that is physiologically required for embryonic development and tissue repair. Aberrant c-Met activation is associated with a variety of human malignancies including cancers of the lung, kidney, stomach, liver, and brain. In this study, we investigated the properties of two novel compounds developed to selectively inhibit the c-Met receptor in antitumor therapeutic interventions. Experimental Design: The pharmacologic properties, c-Met inhibitory activity, and antitumor effects of EMD 1214063 and EMD 1204831 were investigated in vitro and in vivo, using human cancer cell lines and mouse xenograft models. Results: EMD 1214063 and EMD 1204831 selectively suppressed the c-Met receptor tyrosine kinase activity. Their inhibitory activity was potent [inhibitory 50% concentration (IC50), 3 nmol/L and 9 nmol/L, respectively] and highly selective, when compared with their effect on a panel of 242 human kinases. Both EMD 1214063 and EMD 1204831 inhibited c-Met phosphorylation and downstream signaling in a dose-dependent fashion, but differed in the duration of their inhibitory activity. In murine xenograft models, both compounds induced regression of human tumors, regardless of whether c-Met activation was HGF dependent or independent. Both drugs were well tolerated and induced no substantial weight loss after more than 3 weeks of treatment. Conclusions: Our results indicate selective c-Met inhibition by EMD 1214063 and EMD 1204831 and strongly support clinical testing of these compounds in the context of molecularly targeted anticancer strategies. Clin Cancer Res; 19(11); 2941–51. ©2013 AACR.Keywords
Other Versions
This publication has 27 references indexed in Scilit:
- Clinical Implications of MET Gene Copy Number in Lung CancerFuture Oncology, 2010
- Selection Criteria for c-Met-Targeted Therapies: Emerging Evidence for BiomarkersBiomarkers in Medicine, 2010
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in CancerClinical Cancer Research, 2009
- Drug development of MET inhibitors: targeting oncogene addiction and expedienceNature Reviews Drug Discovery, 2008
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Increased expression of HGF and c-met in rat small intestine during recovery from methotrexate-induced mucositisBritish Journal of Cancer, 2000
- Up-regulation of hepatocyte growth factor receptor: An amplification and targeting mechanism for hepatocyte growth factor action in acute renal failureKidney International, 1999
- Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomasNature Genetics, 1997
- Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb budNature, 1995
- Scatter factor/hepatocyte growth factor is essential for liver developmentNature, 1995